This study investigates borderline resectable pancreatic cancer. It explores the feasibility of combining chemotherapy with proton radiotherapy before surgery.
The study evaluates the safety and technical feasibility of this treatment approach. It focuses on how well the treatment is tolerated and its potential to improve surgical outcomes.
- Who can participate: Adults over 18 years with borderline resectable pancreatic cancer may join if they have a confirmed diagnosis and meet specific health criteria.
- Study details: Participants will receive chemotherapy and proton therapy before possible surgery.